Indaptus Therapeutics Reports $5.4 Million Nine-Month Loss
Indaptus Therapeutics reported a net loss of $5.4 million for the first nine months of 2026, down from $12.7 million a year earlier. Third-quarter net loss was $1.0 million versus $3.0 million a year earlier.
Indaptus Therapeutics reported a net loss of $5.4 million for the first nine months of 2026, down from $12.7 million a year earlier, as research and development and general and administrative expenses declined. Third-quarter net loss was $1.0 million, compared with $3.0 million in the prior-year qu…